statistically significant correlations

Related by string. statistically significant correlation * STATISTICALLY . Statistically : statistically significant improvement . demonstrated statistically significant / sig nificant . signifi cant : statistically significant differences . Significant Accounting Policies / Correlations . Correlation : Bloomberg Correlation Weighted . sector correlation seasonality * *

Related by context. Frequent words. (Click for all words.) 62 statistically significant differences 61 inverse association 60 serum calcium 60 cystatin C 60 NHANES III 60 elevated CRP 59 univariate analysis 59 multivariate analyzes 59 fasting insulin 59 serum uric acid 59 atherosclerotic lesions 58 serum concentrations 58 univariate 58 KRAS mutations 58 vitro experiments 58 serum PSA 57 seroprotection 57 shorter telomeres 57 correlations 57 fasting glucose levels 57 apolipoprotein B 56 statistically significant 56 cardiovascular mortality 56 lymph node involvement 56 folate intake 56 oestradiol 56 discontinuations due 56 heavily pretreated 56 differentially expressed 56 laboratory abnormalities 56 tolvaptan 56 mg kg dose 56 serum cholesterol 56 adenoma 56 virologic response 55 correlation 55 pharmacodynamic effects 55 achieved statistical significance 55 antigen PSA 55 carotid intima media 55 antibody titers 55 adenocarcinomas 55 generalizability 55 thromboembolic events 55 immunohistochemical 55 body fatness 55 microvascular complications 55 albuminuria 54 cortical thickness 54 left ventricular dysfunction 54 Pharmacokinetic 54 parkinsonism 54 subgroup analyzes 54 serum albumin 54 nonobese 54 Epidemiological studies 54 squamous 54 nondiabetic 54 mineral density 54 brain lesions 54 vertebral fracture 54 estimated glomerular filtration 54 HbA 1c 54 liver transplant recipients 54 hyperinsulinemia 54 MetS 54 microRNA expression 54 infarct size 54 lymphopenia 54 lipid lowering therapy 54 epidemiologic studies 53 secondary efficacy endpoints 53 osteocalcin 53 mucosal healing 53 placebo controlled clinical trials 53 histone modifications 53 dose limiting toxicities 53 IPSS 53 EGFR mutations 53 lipid lowering drugs 53 coronary artery calcification 53 inflammatory lesions 53 inhibitory effects 53 creatinine levels 53 platelet activation 53 platelet inhibition 53 RRMS patients 53 renal dysfunction 53 cardiovascular morbidity 53 metabolic abnormalities 53 vitro studies 53 thromboembolism 53 genetic polymorphisms 53 chromosomal regions 53 patients evaluable 53 distant metastases 53 ipsilateral 53 confounding variables 53 serologic 53 virologic failure 53 secretin

Back to home page